Activation of the cyclin D1 promoter by arsenite

亚砷酸盐激活细胞周期蛋白 D1 启动子

基本信息

  • 批准号:
    7896859
  • 负责人:
  • 金额:
    $ 11.55万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2009
  • 资助国家:
    美国
  • 起止时间:
    2009-08-01 至 2013-06-30
  • 项目状态:
    已结题

项目摘要

DESCRIPTION (provided by applicant): In the previous funding period we showed that treatment of cultured human keratinocytes with arsenite at submicromolar concentrations induced expression of cyclin D1 and this was accompanied by a shift into the G2 compartment of the cell cycle. Electrophoretic mobility shift assays (EMSA) demonstrated enhanced binding of AP1 and CREB transcription factors to their cognate binding motifs in the cyclin D1 promoter Here we wish to continue the work begun in the previous SCORE funding period by, a) using promoter deletion mutants in luciferase reporter assays to study transcriptional activity and, b) by using chromatin immunoprecipitation (ChIP) as an in vivo assay of transcriptional control of cyclin D1 expression by arsenite. We hypothesize that arsenite is an effector of the MAP kinase stress activated pathway which ultimately activates JNK. To test this we will examine the MAP kinase components of the ERK, JNK and p38 pathways in more detail by using a) chemical inhibitors of components of the MAP kinase pathways and b) dominant negative mutants. Activation of transcription factors resulting from phosphorylation will be demonstrated by western blotting using phosphorylation-specific antibodies. Although our main focus will be on the known components of signaling pathways the possibility exists that arsenite may also bring about phosphorylation of novel elements that may act further upstream. For this reason we also want to examine more global changes in patterns of phosphorylation that occur in response to arsenite using antibody microarrays with a view towards discerning changes in patterns of phosphorylation of proteins that is correlated with the induction of cyclin D1 via transcription factor activation. Finally, we wish to explore the possibility that the inductive effects of arsenite are related to reactive oxygen species as preliminary evidence indicates. If this can be demonstrated this finding will form the basis for future research. PUBLIC HEALTH RELEVANCE: Arsenic is a toxic environmental pollutant and carcinogen. The experiments described are intended to shed light on the molecular mechanism by which arsenic causes cancer in individuals exposed to arsenic over long periods of time. This will ultimately provide targets that may form the basis for new approaches for the prevention of arsenic-caused cancers.
描述(由申请人提供):在之前的资助期内,我们发现用亚微摩尔浓度的亚砷酸盐处理培养的人角质形成细胞可诱导细胞周期蛋白D1的表达,并伴有细胞周期的G2区转移。电泳淌度转变化验(EMSA)展示了增强约束力的AP1和转录因子分子同源绑定图案的细胞周期蛋白D1启动子在这里我们希望继续工作开始之前的分数融资期间,a)使用荧光素酶启动子缺失突变体记者化验研究转录活动和b)通过染色质免疫沉淀反应(芯片)作为体内转录控制细胞周期蛋白D1表达分析的亚砷酸盐。我们假设亚砷酸盐是MAP激酶应激激活途径的一种效应物,最终激活JNK。为了验证这一点,我们将通过使用a) MAP激酶途径成分的化学抑制剂和b)显性阴性突变体来更详细地研究ERK、JNK和p38途径的MAP激酶成分。磷酸化引起的转录因子的激活将通过磷酸化特异性抗体的western blotting来证明。虽然我们的主要重点将放在信号通路的已知成分上,但亚砷酸盐也可能导致可能进一步上游作用的新元素的磷酸化。出于这个原因,我们还希望使用抗体微阵列来研究更多针对亚砷酸盐的磷酸化模式的全局变化,以期识别与通过转录因子激活诱导细胞周期蛋白D1相关的蛋白质磷酸化模式的变化。最后,我们希望探讨亚砷酸盐的诱导效应与活性氧有关的可能性。如果能证明这一点,这一发现将为未来的研究奠定基础。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

MARK L STEINBERG其他文献

MARK L STEINBERG的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('MARK L STEINBERG', 18)}}的其他基金

AREA II CANCER AND AGING
第二领域癌症与衰老
  • 批准号:
    8357148
  • 财政年份:
    2011
  • 资助金额:
    $ 11.55万
  • 项目类别:
Activation of the cyclin D1 promoter by arsenite
亚砷酸盐激活细胞周期蛋白 D1 启动子
  • 批准号:
    8288735
  • 财政年份:
    2009
  • 资助金额:
    $ 11.55万
  • 项目类别:
AREA II CANCER AND AGING
第二领域癌症与衰老
  • 批准号:
    7959165
  • 财政年份:
    2009
  • 资助金额:
    $ 11.55万
  • 项目类别:
AREA II CANCER AND AGING
第二领域癌症与衰老
  • 批准号:
    8166245
  • 财政年份:
    2009
  • 资助金额:
    $ 11.55万
  • 项目类别:
Activation of the cyclin D1 promoter by arsenite
亚砷酸盐激活细胞周期蛋白 D1 启动子
  • 批准号:
    7693131
  • 财政年份:
    2009
  • 资助金额:
    $ 11.55万
  • 项目类别:
Activation of the cyclin D1 promoter by arsenite
亚砷酸盐激活细胞周期蛋白 D1 启动子
  • 批准号:
    8098102
  • 财政年份:
    2009
  • 资助金额:
    $ 11.55万
  • 项目类别:
AREA II CANCER AND AGING
第二领域癌症与衰老
  • 批准号:
    7715271
  • 财政年份:
    2008
  • 资助金额:
    $ 11.55万
  • 项目类别:
AREA II CANCER AND AGING
第二领域癌症与衰老
  • 批准号:
    7561532
  • 财政年份:
    2007
  • 资助金额:
    $ 11.55万
  • 项目类别:
AREA II CANCER AND AGING
第二领域癌症与衰老
  • 批准号:
    7336057
  • 财政年份:
    2006
  • 资助金额:
    $ 11.55万
  • 项目类别:
AREA II GENE EXPRESSION & REGULATION
II区基因表达
  • 批准号:
    7164329
  • 财政年份:
    2005
  • 资助金额:
    $ 11.55万
  • 项目类别:

相似海外基金

University of Aberdeen and Vertebrate Antibodies Limited KTP 23_24 R1
阿伯丁大学和脊椎动物抗体有限公司 KTP 23_24 R1
  • 批准号:
    10073243
  • 财政年份:
    2024
  • 资助金额:
    $ 11.55万
  • 项目类别:
    Knowledge Transfer Partnership
Role of Natural Antibodies and B1 cells in Fibroproliferative Lung Disease
天然抗体和 B1 细胞在纤维增生性肺病中的作用
  • 批准号:
    10752129
  • 财政年份:
    2024
  • 资助金额:
    $ 11.55万
  • 项目类别:
CAREER: Next-generation protease inhibitor discovery with chemically diversified antibodies
职业:利用化学多样化的抗体发现下一代蛋白酶抑制剂
  • 批准号:
    2339201
  • 财政年份:
    2024
  • 资助金额:
    $ 11.55万
  • 项目类别:
    Continuing Grant
Isolation and characterisation of monoclonal antibodies for the treatment or prevention of antibiotic resistant Acinetobacter baumannii infections
用于治疗或预防抗生素耐药鲍曼不动杆菌感染的单克隆抗体的分离和表征
  • 批准号:
    MR/Y008693/1
  • 财政年份:
    2024
  • 资助金额:
    $ 11.55万
  • 项目类别:
    Research Grant
Developing first-in-class aggregation-specific antibodies for a severe genetic neurological disease
开发针对严重遗传神经系统疾病的一流聚集特异性抗体
  • 批准号:
    10076445
  • 财政年份:
    2023
  • 资助金额:
    $ 11.55万
  • 项目类别:
    Grant for R&D
Discovery of novel nodal antibodies in the central nervous system demyelinating diseases and elucidation of the mechanisms through an optic nerve demyelination model
发现中枢神经系统脱髓鞘疾病中的新型节点抗体并通过视神经脱髓鞘模型阐明其机制
  • 批准号:
    23K14783
  • 财政年份:
    2023
  • 资助金额:
    $ 11.55万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
Elucidation of the mechanisms controlling the physicochemical properties and functions of supercharged antibodies and development of their applications
阐明控制超电荷抗体的理化性质和功能的机制及其应用开发
  • 批准号:
    23KJ0394
  • 财政年份:
    2023
  • 资助金额:
    $ 11.55万
  • 项目类别:
    Grant-in-Aid for JSPS Fellows
Role of antibodies in hepatitis E virus infection
抗体在戊型肝炎病毒感染中的作用
  • 批准号:
    10639161
  • 财政年份:
    2023
  • 资助金额:
    $ 11.55万
  • 项目类别:
Defining the protective or pathologic role of antibodies in Post-Ebola Syndrome
定义抗体在埃博拉后综合症中的保护或病理作用
  • 批准号:
    10752441
  • 财政年份:
    2023
  • 资助金额:
    $ 11.55万
  • 项目类别:
Human CMV monoclonal antibodies as therapeutics to inhibit virus infection and dissemination
人 CMV 单克隆抗体作为抑制病毒感染和传播的治疗药物
  • 批准号:
    10867639
  • 财政年份:
    2023
  • 资助金额:
    $ 11.55万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了